PSSD

Lexar and Silicon Motion Collaborate to Unveil Next-Gen Performance Portable SSDs - ARMOR 700 and SL500

Retrieved on: 
Thursday, January 11, 2024
Silicon, Lexar, LAS, TB, Partnership, Silicon Motion, USB, PSSD, SSD, Motion, IP66, Software, SL500, Apple ProRes, Xbox, Dust, Table tennis rubber, IPhone, PlayStation

LAS VEGAS, Jan. 11, 2024 /PRNewswire/ -- Lexar, the leading consumer storage brand announces a collaboration with Silicon Motion, forming a significant partnership that will combine Lexar self-developed storage products with Silicon Motion industry-leading controller chips.

Key Points: 
  • LAS VEGAS, Jan. 11, 2024 /PRNewswire/ -- Lexar, the leading consumer storage brand announces a collaboration with Silicon Motion, forming a significant partnership that will combine Lexar self-developed storage products with Silicon Motion industry-leading controller chips.
  • During the first quarter of 2024, Lexar will be launching two Portable Solid-State Drive (PSSD) products.
  • The partnership will also introduce the highly anticipated portable SSD Lexar SL500.
  • With read and write speeds of up to 2000 MB/s and 1800 MB/s,1 respectively, the SL500 portable SSD is driven by portable SSD controllers from Silicon Motion Technology.

Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases

Retrieved on: 
Thursday, September 30, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Janus, CEST, PASI, Week, Fibrosis, Congress, Journal of the European Academy of Dermatology and Venereology, JAK, CPU socket, Multimedia, Prior, TYK2, Apremilast, Â, Psoriasis Area and Severity Index, Dry, Itch, Psoriasis, Gaps, Immunology, Bristol Myers Squibb, Salford Royal NHS Foundation Trust, Pharmacology, Late, Disease, Comparative effectiveness research, Atopic dermatitis, Risk, Science, Research, Alopecia areata, PSSD, University, Jeff Flake, Neutrophil, BMY, NYSE, University of Manchester, Pharmaceutical industry, Deucravacitinib, the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies, Psoriasis, Bristol Myers Squibb, DEUCRAVACITINIB, THE PHASE 3 POETYK PSO-1 AND POETYK PSO-2 STUDIES, PSORIASIS, BRISTOL MYERS SQUIBB

Bristol Myers Squibb (NYSE: BMY) today announced that data from 19 company-sponsored scientific presentations are being shared at the European Academy of Dermatology and Venereology (EADV) 30th Anniversary Congress taking place September 29 October 2, 2021.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that data from 19 company-sponsored scientific presentations are being shared at the European Academy of Dermatology and Venereology (EADV) 30th Anniversary Congress taking place September 29 October 2, 2021.
  • These data (Presentation #2857) are being presented today during the Late Breaking News Session from 3:45 4:45 p.m. CEST.
  • Bristol Myers Squibb-sponsored abstracts presented at EADVs 30th Anniversary Congress can be found below and accessed online here .
  • Visit this page on BMS.com for more information on Bristol Myers Squibbs scientific approach and resources on dermatologic immune-mediated diseases.